Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Colchicine vs. Aspirin vs. Aspirin (with H2S)

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 23, 2021 7:29pm

216 Views

Post# 32369349

RE:RE:Colchicine vs. Aspirin vs. Aspirin (with H2S)

Seemyvest wrote: I don't understand why they can't talk about testing that they are doing with Covid . I guess it would not be material until it was completed but why not outline it in the recent overview or be open about what it is. I just don't see the purpose of keeping it under wraps.

The only thing that makes sense to me is ... they are working with someone else and have signed an NDA ??????

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December